outbreak
pose
world
pandem
risk
diseas
covid
infecti
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
envelop
nonseg
positivesens
rna
belong
famili
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
virus
caus
pneumonia
requir
intens
care
unit
hospit
case
lead
fatal
outcom
character
sever
case
acut
respiratori
distress
syndrom
ard
cytokin
releas
syndrom
immedi
need
agent
develop
vaccin
date
regist
molecul
treatment
patient
howev
ongo
trial
use
antivir
immunosuppress
immunomodul
drug
demonstr
efficaci
vitro
anim
model
well
small
case
seri
certainli
previou
experi
virus
belong
famili
form
cornerston
current
therapeut
strategi
emerg
face
scientif
commun
address
pandem
provid
rational
use
drug
yet
approv
still
preliminari
scientif
evid
far
therapeut
regim
includ
combin
antivir
drug
support
care
accumul
evid
suggest
infect
associ
proinflammatori
statu
character
high
level
differ
cytokin
includ
interleukin
il
fibroblast
growth
factor
fgf
granulocytemacrophag
coloni
stimul
factor
gmcsf
granulocytecoloni
stimul
factor
gcsf
protein
monocyt
chemoattract
protein
macrophag
inflammatori
protein
alpha
platelet
deriv
growth
factor
pdgf
tumor
necrosi
factor
vascular
endotheli
growth
factor
vegf
critic
ill
patient
requir
admiss
intens
care
unit
icu
display
markedli
high
concentr
gcsf
interestingli
level
also
correl
increas
mortal
moreov
sever
reduct
natur
killer
cell
lymphocyt
express
cell
observ
level
invers
correl
lymphocyt
count
suggest
cytokin
releas
syndrom
may
hamper
adapt
immun
respons
infect
moreov
high
level
ferritin
demonstr
patient
requir
icu
hospit
provid
ration
use
http
receiv
march
receiv
revis
form
april
accept
april
tabl
ongo
clinic
trial
rheumatolog
drug
covid
sever
antirheumat
drug
potenti
treatment
sever
viral
infect
preliminari
experi
suggest
direct
antivir
effect
least
vitro
instanc
chloroquin
cq
hydroxychloroquin
hcq
current
use
face
tocilizumab
monoclon
antibodi
approv
treatment
patient
rheumatoid
arthriti
ra
use
encourag
result
particularli
ill
patient
sinc
massiv
releas
proinflammatori
cytokin
especi
may
occur
lung
epithelium
sever
case
trial
test
efficaci
tocilizumab
sever
patient
ongo
tabl
nonetheless
last
two
decad
rheumatolog
known
incred
revolut
term
avail
treatment
outcom
patient
sever
molecul
use
armamentarium
clinician
molecul
target
toward
specif
mechan
immun
pathogenesi
rheumat
diseas
either
blockingmodul
inflammatori
pathway
specif
cell
subpopul
apoptosi
autophagi
mechan
could
hamper
select
viral
respons
glucocorticoid
gc
among
frequent
use
agent
rheumatolog
clinic
practic
gc
prove
effect
manag
broad
spectrum
diseas
ra
system
lupu
erythematosu
sle
vascul
repres
main
treatment
bridgingsupport
therapi
immunosuppress
glucocorticoid
lipophil
molecul
abl
activ
cytoplasm
receptor
transloc
cellular
nucleu
chang
express
sever
gene
includ
respons
inflammatori
respons
gc
promot
antiinflammatori
protein
transcript
simultan
impair
express
proinflammatori
protein
gc
also
inhibit
leukocyt
migrat
inflamm
site
therefor
surpris
gc
burden
numer
wellknown
side
effect
includ
increas
infect
risk
instanc
ra
patient
use
mg
daili
prednison
increas
risk
infect
requir
hospit
six
time
control
group
hand
improv
ra
diseas
activ
achiev
glucocorticoid
associ
lower
seriou
infect
rate
moreov
drug
appear
independ
predictor
infectionrel
hospit
although
gcrelat
report
infect
bacteri
viral
infect
report
primarili
repres
hsv
hbv
reactiv
debat
question
possibl
usag
gc
pandem
case
diseas
stage
dosageadministr
rout
hydrocortison
show
improv
respiratori
mortal
outcom
bacteri
sever
communityacquir
pneumonia
inconst
efficaci
septic
shock
budesinid
might
reduc
post
viralinflammatorycytokin
product
human
bronchial
epitheli
cell
vitro
discord
result
report
viral
influenza
pneumonia
base
current
evid
report
regard
gc
routin
given
treatment
viral
pneumonia
outsid
clinic
trial
variou
studi
report
gc
administr
patient
sever
influenza
pneumonia
associ
higher
rate
mortal
metaanalysi
conduct
total
patient
influenza
pneumonia
found
use
system
gc
methylprednisolon
differ
dose
rang
report
associ
higher
mortal
rate
risk
ratio
rr
confid
interv
ci
z
p
longer
intens
care
unit
perman
higher
rate
secondari
infect
trial
recruit
statu
includ
use
hydroxychloroquin
use
system
gc
especi
methylprednisolon
merscovinfect
patient
found
one
signific
factor
contribut
increas
mortal
odd
ratio
nonetheless
inform
dose
durat
treatment
report
retrospect
studi
report
recent
cochran
analysi
data
predominantli
base
observ
studi
mostli
low
qualiti
fact
li
analys
outcom
merscov
infect
patient
treat
gc
arabi
et
al
find
rise
death
rate
correl
use
drug
found
delay
lower
respiratori
tract
clearanc
merscov
rna
equal
use
gc
seem
protract
sarscov
viral
clearanc
nonetheless
refer
ard
moment
low
evid
posit
effect
treatment
critic
condit
conclus
evid
support
use
gc
treatment
viral
respiratori
infect
use
remain
controversi
expert
consensu
form
chines
thorac
societi
develop
basic
principl
use
gc
patient
evid
patient
confirm
ard
infect
benefit
dexamethason
provid
use
low
dosag
limit
period
day
reduc
consequ
mortal
thu
support
assist
therapi
elect
indic
mention
gc
inhibit
immun
reaction
act
migrat
chemokin
product
thu
might
lead
prolong
viremia
impair
viral
clearanc
addit
import
forget
corticosteroidrel
advers
effect
especi
cardiovascular
system
anoth
precipit
factor
critic
ill
patient
often
alreadi
comorbid
nonsteroid
antiinflammatori
drug
nsaid
avail
counter
sever
indic
prescrib
wide
symptomat
relief
pain
fever
inflamm
inhibitori
effect
nsaid
prostaglandin
synthas
also
known
cyclooxygenas
cox
reduc
product
prostaglandin
pg
mani
nsaid
block
cox
ibuprofen
nsaid
select
includ
celecoxib
diclofenac
select
target
thought
relev
prostanoid
format
inflamm
acetaminophen
belong
nsaid
effect
cox
activ
remain
controversi
weak
revers
isoformnonspecif
cox
inhibitor
import
mediat
inflamm
respons
viral
infect
contribut
viral
replic
cmv
hcv
virus
belong
flavivirida
famili
recent
document
compound
significantli
inhibit
enzymat
activ
prostaglandin
level
associ
viral
replic
show
therapeut
safeti
efficaci
vitro
vivo
flavivirida
infect
evid
sever
pneumonia
relat
avian
influenza
viru
document
treatment
combin
antivir
nsaid
abl
amelior
pulmonari
inflamm
mice
interestingli
tumorigen
potenti
eicosanoid
receptor
describ
sever
viral
associ
malign
kaposi
sarcomaassoci
herp
viru
support
therapeut
target
antineoplast
purpos
sever
year
ago
author
shown
spike
protein
sarscov
activ
express
via
erknfkb
pathway
studi
provid
key
find
molecular
mechan
involv
viral
infect
induct
inflamm
sarscov
data
inhibitori
effect
ibuprofen
report
anim
model
naproxen
inhibitor
influenza
viru
nucleoprotein
np
drug
may
potenti
present
antivir
properti
recent
clinic
trial
show
combin
clarithromycin
naproxen
oseltamivir
reduc
mortal
patient
hospit
influenza
infect
phase
clinic
trial
ongo
explor
efficaci
addit
naproxen
standard
treatment
critic
patient
hospit
howev
sinc
use
nsaid
acetaminophen
could
associ
mask
symptom
thu
diagnost
delay
prolong
ill
complic
may
common
nsaid
usedboth
respiratori
cardiovascular
patient
acut
respiratori
infect
nsaid
wide
use
evid
suggest
circumst
nsaid
associ
increas
risk
stroke
myocardi
infarct
moreov
larg
random
trial
support
nsaid
may
caus
prolong
ill
complic
taken
respiratori
tract
infect
patient
higher
risk
hospit
critic
diseas
mortal
correl
age
presenc
comorbid
particularli
hypertens
thu
besid
research
evid
relat
specif
peopl
await
regular
symptomat
nsaid
use
recommend
first
line
option
manag
chloroquin
cq
deriv
hydroxychloroquin
hcq
aminoquinolin
compound
current
regist
treatment
prevent
malaria
treatment
number
autoimmun
diseas
cq
develop
extens
use
world
war
ii
prevent
treat
malaria
infect
use
antimalari
limit
due
widespread
resist
plasmodium
hcq
current
part
firstlin
treatment
ra
sle
due
immunomodulatori
effect
mechan
action
still
fulli
elucid
nonetheless
import
aspect
well
known
cq
weak
base
larg
distribut
volum
accumul
high
concentr
almost
bodi
tissu
includ
lung
oral
administr
effici
absorb
present
blood
mainli
proton
molecul
howev
circul
unproton
portion
easili
cross
cell
membran
due
basic
charg
tend
accumul
acid
organel
lysosom
golgi
vesicl
endosom
bind
free
proton
thu
significantli
increas
ph
thu
larg
number
enzym
contain
organel
optim
work
acid
milieu
inhibit
mechan
presum
basi
direct
antiparasit
antivir
immunomodulatori
effect
molecul
although
evid
field
regard
cq
data
show
similar
effect
hcq
addit
current
data
support
mechan
action
two
molecul
equival
hcq
appear
significantli
less
toxic
almost
complet
replac
use
cq
treatment
rheumat
diseas
data
antivir
activ
cq
deriv
experi
perform
human
immunodefici
viru
hiv
hepat
influenza
virus
virus
fact
enter
host
cell
via
endocytosi
follow
fusion
endosom
lysosom
caus
disrupt
host
cell
releas
nucleic
acid
enzym
requir
replic
similarli
envelop
virus
requir
posttransl
modif
envelop
glycoprotein
endosom
enzym
order
complet
matur
process
shed
host
cell
addit
enzymat
activ
requir
multipl
intracytoplasm
signal
cascad
posttransl
modif
lead
cytokin
chemokin
releas
outbreak
sar
earli
studi
perform
identifi
potenti
effect
antivir
treatment
includ
cq
fact
coronavirida
seem
requir
abovement
step
replic
vitro
experi
show
cqtreatment
infect
vero
cell
cell
lineag
commonli
use
assess
viral
replic
vitro
caus
signific
inhibit
viral
replic
drug
ad
within
first
h
postinfect
mark
effect
administ
within
first
hour
interestingli
half
maxim
inhibitori
concentr
dose
rang
easili
safe
reachabl
human
addit
mechan
describ
cq
seem
inhibit
glycosyl
process
angiotensinconvert
enzym
ace
may
effect
affin
sarscov
receptor
contribut
inhibit
viru
cell
entri
anoth
possibl
effect
interf
bond
picalm
phosphatidylinositol
bind
clathrin
assembl
protein
clathrin
imped
endocytosi
viru
vitro
data
demonstr
cq
probabl
phdepend
enzym
inhibitori
effect
significantli
hamper
phosphoryl
mitogenactiv
protein
kinas
mapk
thu
block
replic
human
coronaviru
similarli
select
inhibitor
enzym
fig
februari
wang
et
al
report
first
evid
vitro
efficaci
cq
effect
concentr
ec
valu
achiev
clinic
use
dose
data
subsequ
confirm
author
compar
vitro
antivir
activ
cq
hcq
hcq
demonstr
potent
cq
lower
valu
even
lower
longer
incub
time
effect
may
due
slow
progress
accumul
hcq
higher
concentr
cell
nevertheless
vitro
data
obtain
ideal
experiment
condit
necessarili
impli
effect
vivo
although
vivo
data
current
avail
sarscov
studi
perform
anim
model
coronavirusrel
diseas
report
conflict
result
interest
studi
test
antivir
activ
cq
infect
newborn
mice
femal
pregnant
mother
administ
differ
solut
cq
fivedayold
pup
infect
birth
highest
surviv
rate
depict
group
pup
breastf
cqtreat
mother
surviv
rate
declin
dosedepend
manner
contrari
mortal
rate
untreat
cohort
cohort
pup
receiv
cq
transplacent
moreov
studi
demonstr
immunomodulatori
effect
cq
coronavirusrel
felin
infecti
periton
other
fail
show
signific
effect
possibl
effect
may
contribut
clinic
efficaci
also
given
rational
behind
use
inhibitor
take
account
potenti
benefici
effect
cq
hcq
vitro
studi
clinic
trial
recent
conduct
confirm
data
subject
affect
infect
tabl
preliminari
result
seem
confirm
cq
improv
associ
pneumonia
term
inhibit
pneumonia
exacerb
amelior
lung
imag
shorten
diseas
cours
base
evid
cq
hcq
includ
treatment
protocol
china
worldwid
howev
risk
advers
event
heavili
underlin
recent
systemat
review
includ
six
articl
ongo
clinic
trial
china
cq
seem
effect
limit
replic
gautret
et
al
report
twenti
case
treat
day
hcq
dosag
mgday
plu
azithromycin
show
signific
reduct
viral
carriag
compar
control
author
suggest
azithromycin
ad
hcq
significantli
effici
viru
elimin
rheumatolog
practic
cq
hcq
among
prescrib
medic
patient
ra
connect
tissu
diseas
well
toler
potenti
advers
event
includ
retinopathi
cardiotox
myelotox
rare
cumul
dose
depend
risk
retin
toxic
patient
treat
year
hcq
sle
shown
around
higher
patient
treat
longer
period
associ
acut
infect
cq
hcq
use
short
time
day
accord
expert
consensu
probabl
neglig
risk
advers
event
nevertheless
acut
advers
event
hypersensit
gastrointestin
intoler
requir
attent
especi
critic
ill
patient
may
develop
similar
clinic
manifest
due
addit
cq
hcq
safe
use
pregnanc
nonetheless
ideal
dose
regimen
establish
yet
guidelin
suggest
protocol
use
rheumatolog
ie
mg
bid
cq
mg
bid
hcq
includ
china
itali
although
clinic
trial
vivo
need
found
best
dose
regimen
physiologicallybas
pharmacokinet
model
suggest
load
dose
hcq
mg
bid
first
day
follow
mg
bid
next
four
day
allow
maintain
appropri
plasma
concentr
ten
day
date
antimalari
one
medic
largestalbeit
limit
scientif
background
warrant
use
treatment
protocol
soon
signific
amount
data
avail
clinic
trial
order
verifi
whether
theoret
strong
effect
drug
real
impact
surviv
recoveri
patient
due
excel
safeti
profil
vast
experi
use
remain
pillar
current
treatment
protocol
concern
rheumatologist
immunocompromis
patient
may
higher
risk
develop
turn
speech
around
immunosuppress
drug
may
repres
unpredict
weapon
scenario
inde
coronavirus
shown
caus
sever
diseas
immunosuppress
patient
famili
virus
host
innat
immun
respons
appear
main
driver
lung
tissu
damag
infect
review
mortal
morbid
report
publish
sarscov
merscov
fatal
report
patient
undergo
transplant
chemotherapi
immunosuppress
treatment
age
thu
second
part
review
seek
immunomodulatori
agent
potenti
least
vitro
studi
antivir
activ
thu
exclud
other
azathioprin
n
hwa
lef
member
malononitril
amid
famili
compound
market
therapeut
agent
treatment
ra
autoimmun
disord
renal
transplant
activ
form
teriflunomid
approv
treatment
multipl
sclerosi
name
also
n
exhibit
two
main
mechan
action
inhibit
protein
tyrosin
kinas
activ
inhibit
tcell
prolifer
inde
interfer
de
novo
pathway
pyrimidin
synthesi
inhibit
dihydroorot
dehydrogenas
key
enzym
biosynthesi
pyrimidin
nucleotid
triphosph
pyntp
howev
addit
mechan
activ
may
remain
discov
yet
numer
studi
alreadi
demonstr
sever
antivir
effect
lef
import
cytomegaloviru
cmv
infect
solid
organ
transplant
recipi
american
societi
transplant
transplant
societi
intern
cmv
consensu
group
report
lef
possibl
altern
experiment
therapi
case
extens
resist
standard
antivir
treatment
even
though
random
control
trial
lack
numer
case
report
describ
efficaci
lef
treat
drugresist
cmv
system
ocular
infect
prevent
recurr
viremia
transplant
patient
one
case
report
retrospect
studi
lef
mg
day
follow
mainten
dose
mg
everi
h
result
effect
clear
lowdos
viremia
longterm
cmv
suppress
lung
transplant
must
note
small
cohort
alreadi
take
antivir
agent
three
case
report
describ
lef
could
abl
induc
persist
clearanc
cmv
gene
resist
classic
antivir
therapi
serum
clinic
resolut
transplant
patient
complic
activ
cmv
retin
resist
treatment
system
intravitr
foscarnet
ganciclovir
oral
valganciclovir
case
report
hemopoiet
stem
cell
transplant
recipi
describ
use
lef
alon
combin
antivir
drug
salvag
therapi
recalcitr
cmv
infect
variabl
result
addit
lef
report
treatment
acyclovirresist
perian
herp
simplex
type
infect
hiv
patient
antivir
mechan
cmv
target
mechan
also
appli
fact
even
restor
pyrimidin
nucleotid
triphosph
normal
level
viral
replic
persist
impair
lef
reduc
vitro
spread
cmv
infect
interf
virion
cytoplasmat
assembl
dosedepend
manner
action
appear
independ
level
pyntp
persist
also
cmv
strain
usual
resist
action
ganciclovir
cidofovir
foscarnet
particular
drug
induc
failur
acquir
tegument
extern
membran
cytoplasm
infect
cell
propos
lef
may
interfer
tegument
assembl
inhibit
protein
phosphoryl
phosphoprotein
thu
antivir
activ
specif
cmv
occur
late
stage
viral
assembl
contrast
tradit
anticmv
agent
inhibit
viral
dna
replic
viral
protein
synthesi
seem
affect
two
differ
studi
report
discord
result
viral
dna
product
data
vivo
experi
document
lef
abl
reduc
viral
load
nude
rat
lef
significantli
reduc
cmvinduc
apoptosi
infect
cell
interf
spread
viru
bilger
et
al
show
teriflunomid
role
epsteinbarr
viru
ebv
drug
concentr
lower
normal
use
treatment
ra
prevent
ebvtransform
human
b
cell
prolifer
thank
target
mechan
b
cell
target
action
alter
ebv
latenc
protein
express
fact
increas
express
ebv
nuclear
latent
membran
latter
abl
inhibit
b
cell
prolifer
observ
furthermor
teriflunomid
induc
express
cleavag
level
parp
promot
apoptosi
lymphocyt
vitro
reduct
nuclear
factor
kappalightchainenhanc
activ
b
cell
nfkb
signal
teriflunomid
report
set
drug
inhibit
lytic
ebv
infect
vitro
prevent
initi
step
lytic
viral
reactiv
reduc
immediateearli
lytic
protein
earli
lytic
protein
express
respons
bcell
receptor
block
lytic
viral
dna
replic
intriguingli
lef
shown
influenc
replic
vitro
drug
downgrad
viral
prolifer
inhibit
nfkb
activ
nevertheless
lef
inhibit
mek
map
kinas
pathway
protein
tyrosin
kinas
thu
result
reduct
ico
activ
lead
increas
viral
load
reduc
pyrimidin
pool
teriflunomid
inhibit
replic
viru
agent
argentin
hemorrhag
fever
envelop
negativesens
ssrna
arenaviru
dosedepend
manner
combin
ribavirin
appear
stronger
antivir
activ
monotherapi
mechan
action
seem
explain
antivir
activ
teriflunomid
footandmouth
diseas
viru
rna
viru
member
picornavirida
famili
usual
affect
livestock
breed
martin
et
al
report
preliminari
effect
sever
rna
virus
us
newcastl
diseas
viru
rabi
viru
influenza
viru
bk
polyomaviru
dna
viru
member
polyomavirida
famili
caus
agent
infecti
hemorrhag
cystiti
transplant
recipi
polyomavirusassoci
nephropathi
pvan
potenti
dread
complic
kidney
transplant
sever
year
lef
use
secondlin
therapi
refractori
infect
reduc
mainten
immunosuppress
small
case
seri
prospect
openlabel
trial
analyz
effect
lef
use
alon
combin
drug
tacrolimuseverolimu
fluoroquinolon
pvan
describ
partial
success
viremia
clearanc
better
renal
outcom
nonetheless
report
american
societi
transplant
infecti
diseas
true
efficaci
approach
prove
far
lack
random
controlledtri
addit
metaanalysi
albeit
variou
limit
fail
document
signific
benefit
adjunct
therapi
direct
antivir
effect
dengu
viru
report
lef
despit
drug
seem
abl
reduc
dendrit
cell
migrat
virusinduc
cytokin
releas
induc
vitro
enteroviru
neurotrop
viru
caus
sever
complic
enceph
happen
viral
infect
dengu
fever
recent
promin
role
progress
tissu
damag
sever
diseas
appear
secondari
result
cytokin
releas
syndrom
similarli
infect
seem
close
correl
clinic
sever
diseas
hung
et
al
observ
teriflunomid
significantli
reduc
yield
infect
cell
vitro
abl
induc
reduct
level
compar
control
interestingli
lef
show
robust
efficaci
vitro
vivo
even
respiratori
syncyti
viru
rsv
rna
viru
signific
dosedepend
reduct
rsv
induc
syncytia
format
human
report
drug
use
infect
cotton
rat
mgkgday
reduc
log
pulmonari
viral
load
compar
control
similarli
chong
et
al
report
cmv
infect
rat
antivir
effect
high
concentr
drug
compar
ribavirin
though
lef
show
greater
antivir
efficaci
ribavirin
lower
concentr
doselimit
sideeffect
lef
therapi
liver
damag
lung
diseas
immunosuppress
diarrhea
rash
revers
alopecia
vivo
high
dose
lef
appear
potent
inhibitor
cell
also
partial
inhibitor
b
cell
respons
total
suppress
humor
immun
respons
variou
antigen
mechan
lef
hamper
immun
respons
viral
infect
human
known
although
antivir
effect
lef
variou
agent
gave
demonstr
human
data
avail
optim
dosag
treatment
durat
target
blood
level
teriflunomid
effect
antivir
activ
usag
treatment
doubt
mycophenol
mofetil
mmf
immunosuppress
agent
commonli
use
allograft
reject
differ
organ
transplant
treatment
autoimmun
diseas
mmf
activ
form
mycophenol
acid
inhibit
inosin
monophosph
dehydrogenas
impdh
block
convers
inosin
monophosph
imp
guanosin
monophosph
gmp
hamper
lymphocyt
prolifer
action
share
ribavirin
almost
antivir
mechan
demonstr
mmf
addit
mmf
treatment
reduc
interferon
ifn
mrna
express
level
mdck
infect
cell
inconclus
result
obtain
sever
strain
influenza
viru
discord
evid
regard
action
drug
zika
viru
zkv
zkv
flaviviru
mmf
test
one
studi
drug
could
significantli
reduc
cytopath
effect
west
nilevirusinfect
vero
cell
anoth
one
mmf
demonstr
also
significantli
antivir
activ
japanes
enceph
viru
vitro
vivo
protect
infect
mice
therapeut
index
flaviviru
suscept
mmf
dengu
viru
type
yellow
fever
viru
modoc
viru
montana
myoti
leukoenceph
viru
studi
report
antivir
effect
drug
sever
differ
rna
virus
includ
chikungunya
smallpox
viru
footandmouth
diseas
viru
fmdv
pest
de
petit
rumin
viru
pprv
junin
viru
noroviru
arenaviru
caus
agent
lassa
hemorrhag
fever
reoviru
other
use
also
report
use
cell
could
induc
inhibit
viral
rna
product
clinic
relev
concentr
mgml
persist
effect
time
antivir
effect
numer
virus
mention
appear
due
reduct
gmp
cell
pool
wherea
revers
addict
guanosin
dose
depend
manner
similarli
mmf
inhibit
viral
rna
mrna
protein
synthesi
almost
complet
block
viru
entri
cytopath
effect
human
parainfluenza
viru
type
restrict
recov
guanosin
administr
evid
presenc
anoth
antivir
mechan
mmf
deriv
studi
hepat
c
viru
hcv
seem
drug
abl
inhibit
vitro
vivo
viru
replic
augment
ifnstimul
gene
express
suppress
cell
autophagi
decreas
autophagosom
format
increas
level
express
vitro
merscov
caus
sever
fatal
infect
middl
east
travelerassoci
case
europ
africa
fatal
sinc
emerg
clinic
retrospect
analysi
patient
infect
merscov
show
treatment
mmf
one
predictor
increas
surviv
togeth
disulfiram
andor
seem
abl
synergist
inhibit
merscov
papainlik
proteas
plpr
chan
et
al
found
concentr
mmf
inhibit
cytopath
effect
reduc
viral
load
achiev
plaqu
reduct
vero
cell
infect
combin
show
synergist
activ
despit
evid
author
observ
mmf
ineffect
coronaviridaeinfectedanim
model
fact
one
studi
merscovinfect
marmoset
treat
mmf
develop
sever
andor
fatal
diseas
higher
mean
viral
load
untreat
anim
higher
mortal
one
treat
lopinavirritonavir
barnard
et
al
found
drug
unabl
prevent
viral
replic
lung
sarsinfect
balbc
mice
although
significantli
increas
ribavirin
inefficaci
sarscov
replic
previous
report
interestingli
mmf
could
act
synergist
drug
potenti
antivir
effect
drug
deplet
endogen
gtp
pool
increas
antihbv
activ
penciclovir
lobucavir
diaminopurin
dioxolan
similar
result
obtain
combin
mmf
classic
antivir
drug
abacavir
didanosin
tenofovir
treat
cmv
other
evid
could
allow
clinician
use
mmf
supportdrug
antivir
drug
specif
clinic
contest
even
thou
lack
vivo
clinic
trial
strong
limit
consid
frequent
vitro
activ
correspond
satisfactori
action
vivo
nevertheless
mmf
strong
immunosuppress
agent
reduc
immun
respons
vaccin
transplant
patient
associ
increas
risk
viral
infect
human
herpesviru
herp
zoster
hz
cmv
although
data
remain
inconclus
methotrex
acid
mtx
analogu
antagonist
folic
acid
firstlin
diseasemodifi
antirheumat
drug
dmard
treatment
sever
rheumat
autoimmun
diseas
includ
ra
adultonset
still
diseas
aosd
psoriat
arthriti
psa
effect
relat
abil
inhibit
key
enzym
involv
biosynthesi
purin
pyrimidin
interf
dihydrofol
reductas
dhfr
pathway
mtx
thu
limit
viabil
highli
replic
cell
moreov
mtxinduc
reactiv
oxygen
speci
gener
modul
differ
cell
function
suppress
cytokin
product
cell
prolifer
decreas
adhes
molecul
eselectin
interestingli
dhfr
inhibitor
also
investig
treat
infecti
diseas
current
evid
support
mtx
potenti
treatment
virus
mediat
arthriti
specif
parvoviru
hbv
hcv
hiv
studi
document
proinflammatori
mediat
markedli
decreas
mtx
treatment
virusinduc
arthriti
remark
recent
studi
suggest
hepat
b
reactiv
acceler
liver
diseas
rather
infrequ
manifest
longterm
mtx
treatment
vitro
find
report
antivir
effect
mtx
zkv
inhibit
dhfr
pathway
mechan
similar
publish
result
relat
flavivirus
notabl
author
document
efficaci
intravitr
mtx
treatment
option
patient
necrot
retin
ebvposit
respond
convent
antivir
therapi
mtx
high
risk
reactiv
demonstr
sever
virus
includ
abovement
hbv
ebv
thu
usag
antivir
drug
therapeut
weapon
may
suitabl
one
oldest
know
drug
far
field
rheumatolog
colchicin
inexpens
oral
administ
potent
antiinflammatori
medic
initi
extract
autumn
crocu
use
centuri
mechan
action
inhibit
tubulin
polymer
microtubul
gener
possibl
effect
cellular
adhes
molecul
inflammatori
chemokin
inflammasom
colchicin
current
indic
treatment
gout
famili
mediterranean
fever
pericard
inde
agent
main
treatment
sever
rheumat
condit
activ
inflammasom
releas
proinflammatori
cytokin
key
pathogen
event
alter
organ
actin
cytoskeleton
bind
tubulin
monom
inhibit
polym
format
colchicin
drug
shown
antiinflammatori
effect
pronounc
axi
highli
concentr
neutrophil
macrophag
prolong
action
abil
bind
tubulin
achiev
multipl
cellular
action
includ
inhibit
assembl
nucleotidebind
domain
leucinerich
repeat
protein
inflammasom
addit
effect
neutrophil
colchicin
impair
releas
neutrophil
extracellular
trap
mani
action
demonstr
patient
coronari
diseas
colchicin
block
inflammasom
cytosol
complex
respons
product
patient
acut
coronari
syndrom
downstream
key
inflammatori
cytokin
colchicin
administr
abl
significantli
reduc
transcoronari
gradient
cytokin
similar
reduct
also
level
observ
mucocutan
behcet
diseas
patient
moreov
colchicin
antivir
properti
flavivirida
recombin
demyelin
strain
mous
hepat
viru
demonstr
reduc
viru
replic
sinc
microtubul
crucial
cell
entri
block
neuron
transport
inhibit
rsv
replic
reduc
level
studi
suggest
colchicin
colchicin
deriv
may
influenc
hiv
viral
load
certain
subset
coronaviru
replic
machineri
shown
move
cell
manner
correspond
microtubuleassoci
transport
induc
format
doublemembran
vesicl
infect
cell
similar
viru
sarscov
microtubul
disrupt
may
influenc
viral
replic
also
document
sarscov
accessori
protein
potent
activ
gene
transcript
protein
matur
thu
abl
activ
inflammasom
influenza
viru
encephalomyocard
viru
protein
stimul
secret
follow
activ
inflammasom
thu
make
colchicin
promis
treatment
condit
inde
acut
respiratori
syndrom
relat
associ
wide
releas
proinflammatori
cytokin
includ
interleukin
specif
bind
toll
like
receptor
lead
lung
inflamm
fever
fibrosi
thu
might
use
obtain
suppress
proinflammatori
famili
member
reach
therapeut
effect
viral
infect
moreov
dysregul
activ
inflammatori
activ
myeloid
cell
one
main
pathogen
event
character
infect
coronavirus
colchicin
wellknown
inhibitor
proinflammatori
mechan
induc
neutrophil
thu
propos
adjuv
treatment
rsv
bronchiol
thu
colchicin
broad
antiinflammatori
effect
antivir
properti
summar
fig
hamper
immunosuppress
effect
cheap
may
great
use
unev
case
outbreak
countri
may
sustain
expens
biolog
treatment
colchicin
narrow
therapeut
index
gastrointestin
disturb
may
seen
patient
possibl
limit
usag
due
rel
frequent
occurr
diarrhea
patient
nonetheless
potenti
intraven
administr
may
reduc
side
effect
increas
bioavail
could
suggest
colchicin
may
trial
appropri
patient
popul
reduc
viral
entri
inflammatori
statu
view
openlabel
phase
studi
enrol
patient
diseas
evalu
efficaci
safeti
colchicin
recent
promot
italian
societi
rheumatolog
sir
italian
societi
infecti
tropic
diseas
simit
italian
thorac
societi
aipo
approv
italian
drug
agenc
aifa
encourag
result
provid
case
report
gandolfini
et
al
treat
patient
sign
system
inflamm
plasmat
pgml
normal
rang
pgml
receiv
colchicin
mg
day
mgday
thereaft
benefit
due
worsen
pf
respiratori
function
far
patient
stabl
reinforc
suitabl
option
patient
diseas
known
innat
immun
respons
host
infect
play
crucial
role
induc
proinflammatori
host
factor
lead
tissu
damag
pleiotrop
cytokin
key
role
inflamm
immun
hemopoiesi
major
agonist
molecul
bind
type
induc
similar
biolog
function
precursor
constitut
express
sever
tissu
cell
express
increas
stress
inflamm
wherea
produc
mainli
myeloid
cell
upon
inflammatori
stimul
activ
secret
molecul
upregul
respiratori
viral
infect
interestingli
communityacquir
pneumonia
cap
observ
children
year
age
india
relat
phenotypegenotyp
associ
proinflammatori
cytokin
specif
gene
polymorph
cytokin
level
link
advers
outcom
sever
cap
author
report
mediat
virusinduc
muscarin
receptor
dysfunct
airway
hyperreact
parainfluenza
viru
infect
data
literatur
report
key
mediat
neutrophil
inflamm
influenzainduc
exacerb
chronic
lung
inflamm
use
mous
model
diseas
author
demonstr
crucial
role
drive
neutrophil
recruit
inflamm
whole
phase
viral
infect
block
result
potenti
target
therapeut
treatment
viral
exacerb
chronic
lung
inflamm
author
describ
inflammasom
essenti
signal
pathway
activ
directli
caus
sever
liver
diseas
viral
infect
anakinra
ank
human
antagonist
approv
treatment
ra
aosd
sever
autoimmun
autoinflammatori
disord
includ
tumor
necrosi
factor
receptorassoci
period
syndrom
trap
object
therapi
occupi
enough
receptor
block
cell
signal
rilonacept
canakinumab
molecul
current
use
clinic
practic
treat
autoinflammatori
diseas
rilonacept
longact
solubl
decoy
receptor
bind
prevent
interact
cell
surfac
receptor
approv
treatment
adult
children
year
age
older
cryopyrinassoci
period
syndrom
cap
canakinumab
fulli
human
antibodi
use
therapi
aosd
autoinflammatori
condit
evid
document
control
inflamm
achiev
drug
target
innat
immun
pathway
reduc
inflammatori
tissu
damag
demonstr
cardiovascular
disord
atherosclerosi
diabet
current
evid
antivir
properti
drug
exist
wide
describ
sarscov
capabl
induc
storm
proinflammatori
cytokin
sever
studi
suggest
cell
infect
sarscov
produc
elev
level
strongli
contribut
immunomedi
damag
lung
organ
result
acut
lung
injuri
ali
subsequ
multiorgan
dysfunct
therefor
applic
antagonist
may
reduc
sever
mortal
infect
vital
cytokin
mediat
host
immun
respons
inhibit
tnf
lead
signific
decreas
inflammatori
respons
approach
use
therapi
autoimmun
condit
effect
ra
juvenil
idiopath
arthriti
psa
psoriasi
pso
spondyloarthr
spa
inflammatori
bowel
diseas
five
tnf
inhibitor
tnfi
develop
introduc
clinic
medicin
chimer
monoclon
antibodi
infliximab
solubl
recombin
form
tnf
cellular
receptor
etanercept
two
fulli
human
monoclon
antibodi
adalimumab
golimumab
human
fab
fragment
antitnf
link
polyethylen
glycol
certolizumab
pegol
tnfi
show
differ
molecular
design
rout
administr
potenc
clear
tnf
gene
express
induc
primarili
cell
monocytemacrophag
lineag
varieti
induc
includ
lipopolysaccharid
lp
virus
role
specif
tnf
receptor
tnfr
famili
member
antivir
immun
depend
stage
immun
respons
differ
accord
viru
type
virul
depend
condit
tnfr
induc
cell
survivalapoptosi
program
necrosi
may
play
role
control
viral
infect
risk
bacteri
mycobacteri
infect
increas
patient
receiv
biolog
dmard
therapi
particularli
tnfi
drug
relev
immunosuppress
lead
reactiv
latent
infect
hepat
b
tuberculosi
instanc
hepat
b
c
assess
requir
prior
start
tnfi
patient
posit
hbsag
infliximab
report
case
associ
hbv
reactiv
receptor
ligand
tnf
famili
play
key
role
control
lymphocyt
activ
surviv
immun
respons
tnf
famili
ligand
explor
adjuv
viral
vaccin
agonist
antibodi
tnfr
famili
member
investig
immunotherapi
chronic
viral
infect
alon
combin
checkpoint
blockad
recent
evid
demonstr
potent
antirotaviru
effect
achiev
gene
via
activ
classic
signal
independ
type
ifn
product
moreov
use
infliximab
total
abrog
antirotaviru
effect
tnfi
potent
activ
sever
diseas
mark
excess
product
proinflammatori
cytokin
effect
may
prove
use
viral
infect
highli
character
immun
activ
inflamm
infect
infect
result
deplet
cell
abnorm
cytokin
network
infect
individu
use
signal
expand
reservoir
sever
protein
mimic
regul
signal
pathway
thu
tnfi
consid
addit
therapeut
option
infect
evid
show
key
mediat
virusinduc
muscarin
receptor
dysfunct
airway
hyperrespons
influenza
infectedanim
interestingli
model
etanercept
shown
abl
prevent
virusinduc
airway
hyperrespons
receptor
dysfunct
without
chang
lung
viral
titr
nonetheless
data
support
enough
use
molecul
antivir
drug
potenti
benefici
mechan
patient
could
reduct
tnf
level
appear
increas
especi
critic
stage
moreov
possibl
role
interact
receptor
inde
sarscovrel
sever
respiratori
distress
see
associ
abil
spike
protein
sarscov
downregul
express
addit
sarscov
modul
spike
protein
enzym
tace
activ
via
cytoplasm
domain
lead
viral
entri
potenti
benefici
mechan
tissu
damag
product
sinc
downregul
sarscov
spike
protein
propos
etiolog
event
sever
lung
injuri
author
previous
suggest
tace
antagonist
block
sarscov
infect
attenu
sever
clinic
outcom
studi
confirm
role
promot
pathogenesi
sarscov
infect
fig
potenti
effect
colchicin
infect
provok
dysregul
activ
neutrophil
could
contrast
antineutrophil
effect
colchicin
b
activ
inflammasom
releas
proinflammatori
cytokin
includ
colchicin
act
inhibit
assembl
nucleotidebind
domain
leucinerich
repeat
protein
inflammasom
activ
lower
level
possibl
onset
cytokin
storm
c
may
use
microtubul
replic
machineri
instanc
format
doublemembran
colchicin
inhibitor
tubulin
polymer
microtubul
gener
wide
releas
proinflammatori
cytokin
includ
tnf
observ
phenomena
antagon
colchicin
receptor
suggest
inhibit
signal
may
repres
viabl
chanc
effect
therapi
accordingli
evid
report
markedli
higher
serum
level
togeth
sever
moder
case
phase
random
openlabel
control
trial
efficaci
safeti
adalimumab
especi
patient
particularli
elev
tnf
level
critic
stage
sever
ongo
shanghai
main
outcom
time
clinic
improv
cytokin
produc
innat
immun
cell
mostli
monocyt
macrophag
also
mesenchym
endotheli
cell
fibroblast
recognit
pathogenassoci
molecular
pattern
pamp
damageassoci
molecular
pattern
damp
stimul
acutephas
immun
respons
hematopoiesi
involv
complex
pathogenesi
autoimmun
diseas
like
ra
giant
cell
arter
gca
system
juvenil
idiopath
arthriti
sjia
cytokin
releas
syndrom
cr
cr
possibl
consequ
administr
chimer
antigen
receptor
engin
cell
cart
immunotherapi
recent
approv
treatment
bcell
leukemia
lymphoma
tocilizumab
human
monoclon
antibodi
direct
receptor
capabl
reduc
control
effect
abnorm
product
approv
fda
ema
treatment
ra
diseas
cr
relat
cart
therapi
caus
directli
infus
cart
cell
activ
immun
cell
usual
manifest
clinic
present
rang
smolder
condit
multipl
organ
failur
sinc
clinic
similar
eventu
progress
case
ard
acut
cardiac
injuri
acut
kidney
diseas
requir
icu
monitor
key
role
seem
play
markedli
elev
along
granulocyt
macrophagecolonystimul
factor
gmcsf
use
tocilizumab
iv
mgkg
iv
propos
inde
retrospect
analysi
patient
admit
tongji
hospit
show
inflammatori
cytokin
level
patient
sever
infect
compar
nonsever
significantli
elev
includ
analog
find
report
lei
et
al
cohort
chines
patient
level
peripher
blood
patient
pneumonia
significantli
increas
relat
sever
diseas
even
though
tocilizumab
seem
direct
antivir
effect
elev
serum
level
sever
covid
evid
cytokin
pattern
similar
cr
led
hypothesi
use
drug
treatment
sever
respiratori
infect
whose
manifest
could
correl
abnorm
innat
immun
respons
stimul
random
control
clinic
trial
actual
undergo
china
anoth
start
itali
abovement
tocilizumab
alreadi
use
past
week
offlabel
drug
absenc
specif
therapi
treatment
sever
manifest
covid
icu
noticu
patient
itali
epidem
outbreak
lead
emerg
situat
victim
notabl
anoth
drug
current
avail
treatment
ra
sarilumab
human
monoclon
antibodi
receptor
tocilizumab
avail
iv
well
subcutan
sarilumab
subcutan
possibl
limit
usag
due
slower
effect
acut
scenario
ard
preard
infect
intraven
iv
immunoglobulin
ig
therapeut
prepar
pool
normal
serum
deriv
polyspecif
igg
wide
use
treatment
sever
immunemedi
condit
rheumatolog
diseas
immunomodul
properti
ivig
seem
relat
complex
yet
understood
direct
action
innat
immun
compon
complement
monocyt
macrophag
natur
killer
cell
adapt
immun
cell
tcell
bcell
far
use
ivig
immunomodul
therapi
serum
ig
identifi
one
cardin
constitu
adapt
immun
system
microorgan
especi
virus
bacteria
bond
ig
viral
superfici
antigen
capabl
prevent
viru
cell
penetr
induc
phagocytosi
clearanc
viral
structur
macrophag
neutrophil
final
activ
nk
cell
elimin
infect
cell
enrich
ig
prepar
extract
human
placenta
human
serum
consid
first
antivir
drug
first
exampl
use
immunotherapi
infect
intramuscular
ig
first
use
prevent
hav
measl
later
intraven
prepar
reduc
anaphylaxi
risk
specif
ig
prepar
develop
donor
high
titer
desir
antibodi
call
hyperimmun
prepar
use
prevent
treat
varieti
viral
infect
hav
rabi
cmv
varicella
zoster
viru
vzv
measl
etc
deriv
blood
healthi
donor
ivig
contain
panel
polyclon
ig
direct
wide
varieti
common
microorgan
interest
work
kraus
et
al
evalu
presenc
specif
antimicrobi
activ
commerci
kit
ivig
show
prepar
signific
activ
hsv
cmv
vzv
ebv
measl
mump
rubella
parvoviru
reason
ivig
employ
substitut
treatment
patient
hypogammaglobulinemia
primari
secondari
defici
childhood
acquir
immunodefici
syndrom
aid
prevent
common
opportunist
viral
bacteri
infect
mani
exampl
literatur
report
use
ivig
prevent
treatment
opportunist
infect
immunocompromis
patient
secondari
immunosuppress
therapi
aid
bone
marrow
transplant
bmt
cmv
common
herp
viru
infect
around
gener
popul
transplant
patient
ivig
administ
acyclovir
ganciclovir
seem
capabl
prevent
cmv
relat
complic
retrospect
studi
ljungman
et
al
show
addit
benefit
ivig
combin
standard
antivir
therapi
compar
antivir
therapi
alon
treatment
cmv
gastrointestin
diseas
bmt
case
seri
show
ivig
could
possibl
treatment
strategi
activ
cmv
infect
immunocompromis
patient
common
respiratori
virus
like
human
metapneumoviru
hmpv
adenoviru
adv
rsv
emerg
import
etiolog
player
seriou
respiratori
infect
immunocompromis
patient
follow
bmt
renal
transplant
ivig
demonstr
direct
antivir
activ
vitro
hmpv
rsv
mani
case
report
case
seri
highlight
efficaci
regimen
includ
ribavirin
cidofovir
ivig
complet
resolut
symptom
pneumonia
caus
abovement
virus
ivig
also
use
prophylaxi
vzv
infect
newborn
expos
viru
birth
effect
treatment
dissemin
vzv
infect
ivig
seem
abl
reduc
recurr
genit
manifest
hsv
shown
reduc
burden
bk
polyomaviru
proport
transplant
patient
west
nile
wn
fever
caus
flaviviru
provok
enceph
mening
mous
model
commerci
ivig
israel
diseas
endem
show
efficaci
prevent
develop
diseas
administr
virem
phase
ie
administ
day
inocul
viru
efficaci
directli
proport
dose
administ
interestingli
ivig
deriv
usa
donor
diseas
endem
show
protect
effect
way
ig
specif
serum
antibodi
could
also
associ
increas
risk
infect
promot
viral
entri
suscept
cell
mechan
antibodydepend
enhanc
ade
firstli
describ
flavivirida
hiv
ebola
virus
involv
specif
cellular
receptor
like
fc
receptor
fcr
complement
receptor
type
process
recent
propos
fu
et
al
possibl
mechan
lung
damag
sarscov
pneumonia
particular
viral
surfac
antigen
shost
antibodi
antispik
igg
complex
promot
fcrmediat
intern
viru
macrophag
ade
activ
intracellular
signal
fcr
interact
result
upregul
releas
proinflammatori
cytokin
respons
sever
lung
diseas
moreov
observ
appear
antivir
igg
coincid
patient
onset
acut
respiratori
diseas
studi
identifi
ivig
agent
abl
satur
fcr
possibl
prevent
lung
damag
sarscov
infect
despit
systemat
review
sar
treatment
show
inconclus
result
retrospect
analysi
ivig
treat
patient
possibl
therapeut
role
ivig
could
hypothes
janu
kinas
jak
intracellular
signal
compon
function
downstream
mani
cytokin
four
member
includ
jak
famili
nonreceptor
tyrosineprotein
kinas
jak
play
key
role
immun
respons
also
involv
hematopoiesi
jak
kinas
found
cell
cytoplasm
associ
key
cytokin
receptor
activ
kinas
upon
activ
jak
induc
downstream
activ
signal
transduc
activ
transcript
stat
protein
transduct
signal
final
transcript
sever
gene
involv
immun
cell
prolifer
differenti
activationinhibit
surviv
apoptosi
immun
respons
pathogen
includ
virus
signal
occur
via
jakstat
pathway
includ
type
regul
complex
type
ii
ifn
mediat
via
complex
ifn
primari
defens
pathogen
strong
antivir
activ
known
import
therapeut
option
success
treatment
hbv
hcv
effect
hepat
e
infect
chronic
delta
hepat
requir
type
type
ii
ifn
signal
pathway
crucial
lymphocyt
develop
function
viral
infect
induc
express
proinflammatori
cytokin
tnf
well
chemokin
gener
would
consider
upregul
viral
infect
studi
found
distinct
antivir
activ
correl
virusspecif
express
level
interferonstimul
gene
isg
subset
instanc
isg
strong
antivir
effect
other
promot
viral
replic
vitro
macrophag
produc
signific
level
chemokin
dendrit
cell
dc
especi
plasmacytoid
dc
respond
viru
infect
dose
depend
induc
high
express
contrari
rapid
pdc
apoptosi
moreov
downregul
product
nk
cell
product
lead
rapid
induct
adapt
immun
respons
jak
inhibitor
jaki
small
molecul
target
intracellular
cytokin
signal
number
jaki
current
use
investig
use
sever
autoimmun
system
diseas
ra
pso
psa
also
approv
investig
indic
tofacitinib
specif
baricitinib
mainli
inhibit
upadacitinib
soon
market
demonstr
greater
select
respect
jaki
antivir
potenti
sinc
may
lower
proinflammatori
respons
mediat
virus
instanc
baricitinib
induc
dose
depend
inhibit
intriguingli
baricitinib
inhibit
protein
kinas
regul
endocytosi
use
infect
lung
cell
bind
may
possibl
interrupt
passag
viru
cell
also
intracellular
assembl
viru
particl
baricitinib
therapeut
dose
either
mg
mg
daili
suffici
inhibit
thu
suggest
trial
appropri
covid
popul
hand
therapi
target
jak
complex
may
interfer
normal
antivir
respons
includ
inhibit
activ
may
potenti
increas
risk
infect
andor
reactiv
sever
viral
infecti
diseas
includ
dose
depend
risk
vzv
observ
tofacitinib
baricitinib
thu
usag
care
evalu
moreov
select
jaki
fedratinib
target
jaki
abl
inhibit
respons
implic
diseas
cytokin
releas
syndrom
may
benefici
other
granulocytemonocyt
coloni
stimul
factor
gmcsf
fundament
cytokin
growth
factor
involv
prolifer
matur
myeloid
precursor
granulocyt
monocyt
macrophag
express
receptor
fact
wide
use
revers
neutropenia
induc
cytotox
agent
howev
extens
evid
gmcsf
abl
prime
macrophag
transcrib
secret
cytokin
respons
common
advers
event
fever
myalgia
follow
outbreak
huang
et
al
demonstr
patient
display
markedli
increas
plasma
level
gmcsf
compar
healthi
popul
suggest
gmcsf
may
play
role
context
cr
addit
patholog
studi
demonstr
signific
macrophag
infiltr
lung
patient
die
sarscov
infect
share
signific
similar
recent
detail
analysi
perform
cell
peripher
blood
patient
interestingli
high
level
cell
express
gmcsf
found
patient
along
gmcsfsecret
compar
healthi
control
even
intriguingli
cell
express
gmcsf
detect
exclus
icu
patient
thu
suggest
potenti
contribut
gmcsf
cr
data
support
evid
human
pulmonari
microvascular
endotheli
cell
hpmec
abl
secret
gmcsf
follow
inflammatori
stimulu
lp
suggest
potenti
import
role
pathogenesi
ard
increas
level
gmcsf
present
bal
fluid
addit
anim
model
demonstr
gmcsf
neutral
effect
reduc
sever
neuroinflamm
induc
cart
therapi
neg
effect
efficaci
multipl
gmcsf
gmcsf
receptor
inhibitor
namilumab
mavrilimumab
otilimab
current
investig
treatment
ra
preliminari
data
seem
promis
blockad
pathway
may
repres
addit
interest
experiment
approach
treat
cr
patient
fight
one
greatest
challeng
medic
scienc
entir
human
commun
face
last
centuri
search
discoveri
weapon
could
possibl
amelior
diseas
eagerli
await
crack
door
open
alreadi
exist
drug
rheumatologist
armamentarium
tabl
summar
current
use
agent
antivir
effect
suppos
mechan
action
moreov
aim
give
new
idea
toward
rheumatolog
approach
treatment
infect
notwithstand
fight
togeth
profession
figur
collabor
everi
day
treat
patient
